New Delhi, November 09, 2018: Collaboration of Urethane Systems business unit with Polymer Science and Engineering department extended to CUMIRP Cluster M
Access to academic research on structure-property relationships, 3D printing and additive manufacturing
Next-generation materials for layer based manufacturing techniques
Cologne – LANXESS’ Urethane Systems business unit (URE) decided to prolong and extend its collaboration with the Center for UMass/Industry Research on Polymers (CUMIRP) at the University of Massachusetts Amherst, USA. From October 2018 onwards URE will additionally participate in Research Cluster M on Mechanics & Advanced Manufacturing of Polymers and Composites.
One of the cluster research areas is additive manufacturing technology innovation and next-generation 3D printing formulations. The focus in these efforts is to generate resins that have superior interfacial strength and enhanced sintering or reaction kinetics. Additive manufacturing is in the strategic focus of LANXESS Urethane Systems.
The CUMIRP Cluster M mainly works on understanding structure-process-property relationships of next-generation materials together with the development of new process methods or additives that simultaneously improve processability, and engineering properties. In the last few years the cluster has focused on applying this know-how to development of novel materials for additive manufacturing. “By joining this cluster, we will have access to the most recent technological developments in the field of 3D printing and additive manufacturing as well as to unique testing equipment targeted to screen materials for additive manufacturing and be part of a broader industrial community in this field,” says Dr. Polina Ware, head of Global Research and Development at URE. “Further, this collaboration will strengthen LANXESS’ relationship with UMass overall and help us in the long run to attract top talents.”
LANXESS expects cost savings from the collaboration through sophisticated, highly efficient solutions as well as benefits in business competition by using progressive technologies and the recruiting of qualified specialists. Furthermore, access to other companies who could be potential partners and/or customers will be provided.
Forward-Looking Statements:
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person’s officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.
LANXESS is a leading specialty chemicals company with sales of EUR 9.7 billion in 2017 and about 19,200 employees in 25 countries. The company is currently represented at 74 production sites worldwide. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.
Corporate Comm India(CCI NewsWire)
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…